# OnCo record imforte (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/imforte/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "imforte", "NCT05091567" ;
  schema:name "IMforte"@en ;
  schema:description "IMforte produced the first maintenance treatment ever approved for extensive-stage small-cell lung cancer, adding lurbinectedin to the immunotherapy that continues after chemotherapy."@en ;
  schema:url <https://onco.cc/trials/imforte/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05091567>, <https://www.roche.com/media/releases/med-cor-2025-10-03b> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2021-11-18" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:companies <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/pharmamar/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-imforte-lancet-2025/> .